Rankings · Price against the business
Most free cash flow per dollar of price
Graded A or B, ranked by free cash flow over the last twelve months divided by market value. Banks and insurers are left out, and yields above 50% are treated as data problems rather than bargains.
125 companies meet this test
Figures as of November 15, 2026
| # | Company | Grade | Free cash flow yield | P/E | Revenue growth | Market value |
|---|---|---|---|---|---|---|
| 1 | GMABGenmab A/S | B+ | 35.7% | 3.34 | +18% a year | $3.2B |
| 2 | NRIXNURIX THERAPEUTICS, INC. | A+ | 21.9% | 6.73 | — | $1.7B |
| 3 | BCRXBIOCRYST PHARMACEUTICALS, INC. | B | 18.7% | — | +45% a year | $2B |
| 4 | HRMYHARMONY BIOSCIENCES HOLDINGS, INC. | B+ | 17.5% | 11.14 | +22% a year | $2B |
| 5 | TAKTakeda Pharmaceutical Company Limited | A | 16.0% | 50.12 | +3% a year | $34.4B |
More rankings
A ranking orders companies by one stated measure. It is not a recommendation, and it says nothing about whether any share price is reasonable.